文献速递白血病造血干细胞移植与细胞治疗

可测量残留病灶检测较二代测序突变更能预测双等位CEBPA突变急性髓系白血病结局

Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
PubMed 文献 · Br J Haematol · 2020-02-23

本研究纳入124例新诊断双等位CEBPA突变急性髓系白血病患者,比较二代测序突变风险与多参数流式细胞术可测量残留病灶(MFC-MRD)检测对结局的预测价值。结果显示NGS低危是治疗前参数中唯一有利独立因素,而MRD高危是包括治疗前后参数中唯一不良独立因素,复发患者接受异基因造血干细胞移植后仍可获得较好结局。

要点

  • NGS低危(无附加突变或GATA2突变)是治疗前参数中唯一有利独立因素。
  • MRD高危(两轮巩固后持续阳性或任何时间MRD阴性丢失)是唯一不良独立因素。

核心结论

  • NGS低危是治疗前参数分析中的有利因素,MRD风险分层是治疗前后参数中的独立预后因素。
  • 复发患者后续接受异基因造血干细胞移植仍可获得较好结局。

主要发现

  • 无附加突变和伴GATA2突变定义为NGS低危,是治疗前参数中唯一有利独立因素(对累积复发率和无复发生存率)。
  • 两轮巩固治疗后持续MRD阳性及任何时间MRD阴性丢失定义为MRD高危,是包括治疗前后参数中唯一不良独立因素(对累积复发率、无复发生存率和总生存率)。
  • 在第二次完全缓解和未缓解患者中,接受异基因造血干细胞移植者获得更优总生存。

临床怎么用

  • 对双等位CEBPA突变AML患者,应结合NGS突变谱与MFC-MRD动态监测进行风险分层。
  • MRD高危患者需密切监测复发,复发后可考虑异基因造血干细胞移植以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukaemia (AML) patients with biallelic mutations of CEBPA (bi CEBPA) have a 30-50% relapse rate. This study established the value of mutations based on next-generation sequencing (NGS) and multiparameter flow cytometric measurable residual disease (MFC-MRD) detection and compared the outcomes. From 2014 to 2018, 124 newly diagnosed bi CEBPA AML patients were treated. The median age was 37·5 (16-69) years. The 3-year cumulative incidence of relapse (CIR), relapse-free survival (RFS) and overall survival (OS) were 33·0%, 64·7% and 84·3%, respectively. Patients without additional mutations and with GATA2 mutations were defined as 'NGS low risk', which was the only favourable independent factor for CIR and RFS of pretreatment parameters. Patients with sustained positive MRD after two consolidation cycles and MRD negative losses at any time were defined as 'MRD high risk', which was the only poor independent factor for CIR, RFS and OS, including pretreatment and post-treatment parameters. In CR2 and non-remission patients who underwent allo-HSCT, superior OS was achieved. We conclude that NGS low risk was a favourable factor in the analysis of pretreatment parameters. MRD risk stratification was an independent prognostic factor in pretreatment and post-treatment parameters. Relapsed patients still have a favourable outcome followed by allo-HSCT.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang J, Lu R, Wu Y, et al. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. Br J Haematol. 2020. PMID: 32090321. doi:10.1111/bjh.16535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。